Please login to the form below
PD-1
This page shows the latest PD-1 news and features for those working in and with pharma, biotech and healthcare.
Sanofi completes acquisition of immuno-oncology specialist Synthorx
In the league of top pharma companies, Sanofi has been a bit late to the cancer immunotherapy category, but has been making a way into the market through its PD-1 ... inhibitor Libtayo (cemiplimab) – the sixth PD-1/PD-L1 to reach the market.
Latest news
-
FDA starts priority review of BMS Opdivo/Yervoy in first-line NSCLC
The FDA has started a priority review of PD-1 inhibitor Opdivo (nivolumab) in combination with BMS’ low-dose CTLA4 inhibitor Yervoy (ipilimumab) in previously-untreated NSCLC patients whose tumours ... If approved, BMS will finally have a regimen that
-
BMS expands collaboration with Nektar, sending shares soaring
The new collaboration will expand testing of Nektar’s bempegaldesleukin (bempeg) and BMS’ PD-1 inhibitor Opdivo (nivolumab) in to five types of cancer, up from the previous three. ... As an answer to Opdivo’s apparent inability to demonstrate
-
Pfizer signs $507m cancer deal with Effector Therapeutics
It has already signed previous collaboration deals with Pfizer and Merck KGaA to study tomivosertib in combination with Bavencio (avelumab) and with Merck &Co to evaluate the candidate with blockbuster ... 1 inhibitor Keytruda(pembrolizumab).
-
Boehringer Ingelheim to manufacture first biologic in China under new reforms
German pharma will manufacture BeiGene's PD-1 inhibitor. German pharma Boehringer Ingelheim will be the first company in China to manufacture a biologic, under new regulations aimed at accelerating the ... BeiGene's PD-1 inhibitor tislelizumab was
-
Seattle, Astellas bag speedy FDA okay for bladder cancer drug
as well as immunotherapy with PD-1/PD-L1 inhibitor drugs. ... In that group Padcev had an ORR of 71% when given alongside Merck &Co’s PD-1 inhibitor Keytruda (pembrolizumab) – around twice the level of the standard fallback therapy carboplatin –
More from news
Approximately 26 fully matching, plus 326 partially matching documents found.
Latest Intelligence
-
Encouraging signs in biomarker R&D
The confounding issue is that, in the case of PD-1/PD-L1 drugs, each developer uses its own companion diagnostic that is required to prescribe the drug. ... Harmonisation has been addressed in this case by the development of a ‘complementary’
-
2019: CRISPR and therapeutic gene editing comes of age
The cells were gene-edited to lack PD-1, the immune checkpoint targeted by drugs such as Merck &Co’s Keytruda (pembrolizumab) and Bristol-Myers Squibb’s Opdivo (nivolumab), and the ... hope was that - without the brake of PD-1 – the edited cells
-
Immuno-oncology in 2019: the rapid evolution continues
However this class of drugs aren’t miracle cures: many patients and tumour types do not respond to PD-1/PD-L1s – the overall response rate (ORR) is commonly well below ... PD-1/PD-L1 inhibitors: Keytruda is King, but the market is developing fast.
-
Drug launches to watch in 2019
9. Vitrakvi – a novel addition to the immune-oncology market. Earlier this year Merck &Co/MSD became the first company to secure approval for a ‘tissue agnostic’ drug when its ... 1 inhibitor Keytruda (pembrolizumab) was backed for cancers
-
Is China ready for a pharmaceutical gold rush?
The programmed cell death 1 (PD-1) immune checkpoint inhibitor works by restoring the immune system’s ability to fight cancer tumours. ... Competition time. At the same time, Merck’s PD-1 agent, Keytruda, is hot on Opdivo’s heels.
More from intelligence
Approximately 0 fully matching, plus 34 partially matching documents found.
Latest appointments
-
Crescendo Biologics appoints Dr Kevin Johnson as chairman
Crescendo's discovery programmes are focused on the development of innovative medicines for the treatment of cancer, including its proprietary Humabody Drug Conjugates (HDCs) and checkpoint modulators such as ... 1 Humabodies.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Oncosec
with the latter potentially enabling OncoSec to address a great unmet medical need in oncology: anti-PD-1 non-responders.
-
Parachuting Behind Enemy Lines: OncoSec’s Attack on Visceral Tumors via Its New Visceral Lesion Applicator (VLA)
patients whose disease was truly refractory to anti–PD-1 antibody monotherapy.17. ... Initial report of intratumoral tavokinogene telseplasmid with pembrolizumab in advanced melanoma: an approach designed to convert PD-1 antibody progressors into
-
Immuno-oncology: The market opportunity for PD-1/PD-L1s
Of these therapies, immune checkpoint inhibitors are showing particular promise.Our latest infographic is a snapshot of the PD-1/PD-L1 market at this time.
-
How pembrolizumab will change the management of advanced lung cancer
The Phase III KEYNOTE-024 trial assessed pembrolizumab compared to standard of care (SOC) platinum-based chemotherapies in patients with previously untreated stage IV, programmed cell death ligand 1 (PD-L1) ... In light of these findings, it is
-
A stumble, but not a fall – what’s next for Opdivo?
Until things took a turn for the worse. . Opdivo works via PD-1 immune checkpoint inhibition, which involves reactivating T-cells (a subtype of white blood cell) and decreasing tumor growth.
More from PMHub
Approximately 0 fully matching, plus 7 partially matching documents found.
Featured jobs
-
Vice President
-
Competitive Salary Offered
-
Principal Medical Writer
-
£48 - 58, 000 according to skills and experience benefits
- Senior Medical Writer, MedComms Agency
-
Salary TBC
- Account Director or Senior Account Director
-
Salary TBC
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
-
Consultant
-
competitive salary
- Director of Scientific Services, Medical Communications, Six fig...
-
Six figure salary
- Account Manager– Medical Communications
-
(Negotiable - depending on experience)
Subscribe to our email news alerts
- Lilly will aim for one $1bn-$5bn deal per quarter in 2020
- Moving annual total (MAT)
- Novartis gets EU approval for multiple sclerosis therapy Mayzent
- Immuno-oncology, personalised medicine continues to drive pharma sector
- FDA delays decision on Intercept's NASH drug by three months
- Roche’s SMA treatment risdiplam hits another clinical target
- New coronavirus sees drug developers scramble to develop a vaccine
- Sanofi completes acquisition of immuno-oncology specialist Synthorx
- Roche's checkpoint inhibitor fails pivotal urothelial cancer trial
- Epizyme wins FDA approval for epithelioid sarcoma treatment
- Pharma Brand Planners' Blog (Part 8)
- Happy Chinese New Year 2020 - The Year of The Rat
PMHub
Say Communications
Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...
Latest intelligence
- Happy Chinese New Year 2020 - The Year of The Rat
- A fond farewell to The Year of the Pig...
- White Paper for download - Explaining the price of your product
- In this white paper, he breaks down the pricing options available to you, shares stories from his extensive experiences, and talks you through how to better define your pricing, step-by-step....
- OPEN Health expands offering with the launch of a new Learning & Development specialist team
- Enhanced expertise to deliver impactful internal training programmes for healthcare clients...
Quick links
Infographics
